Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 22, 2021

Atreca, Gates MRI partner to develop antibody for malaria prevention

Clinical-stage biotechnology firm Atreca has signed a licensing agreement with the Bill & Melinda Gates Medical Research Institute (Gates MRI) for the development of a monoclonal antibody to prevent malaria.

Gates MRI plans to develop MAM01/ATRC-501 as a malaria prevention treatment for paediatric and infant patients. Credit: NIAID / commons.wikimedia.org.